[144] UroGen Pharma Ltd. SEC Filing

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) – Form 144 filing. An unidentified insider has notified the SEC of an intended open-market sale of 7,522 ordinary shares through Oppenheimer & Co. on or after 28 Jul 2025. Based on the filer’s estimate, the block is worth $142,541.90, implying an indicative price of roughly $18.95 per share. The shares represent 0.016% of the company’s 46.1 million shares outstanding, a small fraction of float but still a required disclosure under Rule 144.

The shares stem from 16,500 restricted stock units granted and vested on 31 Jan 2024. The filer reports no other URGN share sales in the prior three months. The filer also certifies that no undisclosed material adverse information is known. While modest in size, the transaction flags upcoming insider liquidity and may be watched as a sentiment signal.

Positive

• None.

Negative

• Insider intends to sell 7,522 shares (~$143k), which can be interpreted as a mildly negative sentiment signal despite small relative size.

Insights

Equity Analyst

TL;DR: Small insider sale; limited dilution risk but potential sentiment drag.

The proposed 7,522-share disposition (~$143k) equals just 0.016% of outstanding shares, so supply pressure is negligible. However, insider intent to monetize recently vested RSUs can be interpreted as lukewarm confidence in near-term upside, especially for a biotech awaiting catalysts. No sales in prior quarter slightly offsets the concern. Overall impact is modestly negative for sentiment, neutral for fundamentals.

Corporate Governance Specialist

TL;DR: Routine Rule 144 notice; governance compliance intact.

The filing shows adherence to Rule 144 disclosure and certification of no undisclosed adverse information, reflecting sound compliance. The sale follows a standard equity compensation vesting schedule, and the filer uses a reputable broker, reducing execution risk. Absent larger insider selling patterns, governance implications are neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	7522	142541.90	46107451	07/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	01/31/2024	Restricted Stock Units	From the Issuer			16500	01/31/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many UroGen Pharma (URGN) shares are being sold under this Form 144?

The filer plans to sell 7,522 ordinary shares.

What is the estimated value of the URGN shares to be sold?

The aggregate market value is $142,541.90.

When may the insider sell the URGN shares?

The approximate sale date disclosed is 28 July 2025.

What percentage of URGN’s shares outstanding does the sale represent?

About 0.016% of the 46,107,451 shares outstanding.

How were the shares acquired by the insider?

They originated from 16,500 restricted stock units granted on 31 Jan 2024.

Were there any URGN insider sales in the prior three months?

The filer reported none in the past three months.